Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Spontaneous remission in canine myasthenia gravis
Bayer 2255.jpg © Bayer
Myasthenia gravis is thought to be a rare autoimmune disease in dogs. Canine myasthenia gravis (MG) is used in studies to assess the effect of immunotherapies in this disease in humans. These results question the value of these studies.

The natural course of autoimmune canine MG was determined in 53 dogs with muscular weakness and a positive acetylcholine receptor antibody titer. Dogs were treated with anticholinesterase therapy, without immunosuppression.

Spontaneous clinical and immunologic remission occurred in 47 of 53 dogs within an average of 6.4 months. Neoplasia was identified in the six dogs that did not spontaneously remit. This study questions the value of using canine MG in studies designed to assess the effect of immunotherapies.

Source: Shelton GD, Lindstrom JM. (2001): Spontaneous remission in canine myasthenia gravis: Implications for assessing human MG therapies. In: Neurology 2001 Dec 11;57(11):2139-2141




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Fluorescein sodium-guided resection of intracranial lesions in dogsmembers
Twenty-two dogs with intracranial lesions were enrolled in this prospective case series. The objectives were to evaluate the safety of an intraoperative fluorescein sodium (FS) injection and elucidate the relationships between the MRI findings, pathological diagnoses, and intraoperative staining characteristics of intracranial lesions in 22 dogs.

  • Ultrasound and clinical findings in cats with urethral obstructionmembers
  • Novel technique to measure plasma lipids in diabetic dogsmembers
  • Prevalence and disease associations in feline thrombocytopeniamembers
  • Optic neuritis in dogs: an updatemembers
  • Brachycephalic airway syndrome - differences between pugs and French bulldogsmembers
  • Prognostic factors in cats with HCMmembers
  • Ureteral Papilla Implantation in Cats Undergoing Renal Transplantationmembers
  • Storage lesion in canine packed erythrocytesmembers
  • Drug-induced infiltrative lung disease with cytarabine and prednisonemembers
  • Laparoscopic-assisted Gastropexy and the Gastrointestinal Transit Time in Dogsmembers
  • Transpalpebral ultrasonographic evaluation and measurement of the optic nerve members
  • Squamous cell carcinoma mimicking orbital myofibroblastic sarcomamembers


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved